Autoantibodies against MJ/NXP2 have been extensively associated with the risk of cancer in IIM patients (27, 56–58), even though some large studies (59) and meta-analyses (60) failed to demonstrate an association with malignancy compared to other patient subsets. The gene discussed is MORC3; the disease is cancer.